Table 2.
Association between MDM2 SNP309 status and clinicopathological characteristics
| Total, n (percent) | T/T, n (percent) | T/G, n (percent) | T/T + T/G, n (percent) | G/G, n (percent) | Pa | |
| Patients | 557 (100) | 111 (20) | 263 (47) | 374 (67) | 183 (33) | |
| Age (median, year) (n = 557) | 57 | 56 | 56 | 58 | ||
| Tumor size (n = 557) | 0.49 | |||||
| ≤ 2 cm | 202 (36) | 49 (44) | 88 (33) | 137 (37) | 65 (36) | |
| 2 cm to ≤ 5 cm | 286 (51) | 53 (48) | 139 (53) | 192 (51) | 94 (51) | |
| >5 cm | 57 (10) | 6 (5) | 28 (11) | 34 (9) | 23 (12) | |
| Unknown | 12 (2) | 3 (3) | 8 (3) | 11 (3) | 1 (1) | |
| Node status (n = 557) | 0.63 | |||||
| Negative | 321 (58) | 59 (53) | 159 (60) | 218 (58) | 103 (56) | |
| Positive | 198 (35) | 42 (38) | 88 (34) | 130 (35) | 68 (37) | |
| Unknown | 38 (7) | 10 (9) | 16 (6) | 26 (7) | 12 (7) | |
| Histology (n = 557) | 0.44 | |||||
| IDC | 486 (87) | 97 (87) | 233 (89) | 330 (88) | 156 (85) | |
| ILC | 20 (4) | 3 (3) | 8 (3) | 11 (3) | 9 (5) | |
| Others | 51 (9) | 11 (10) | 22 (8) | 33 (9) | 18 (10) | |
| ER status (n = 557) | 0.14 | |||||
| Positive | 344 (62) | 68 (61) | 153 (58) | 221 (59) | 123 (67) | |
| Negative | 181 (32) | 33 (30) | 95 (36) | 128 (34) | 53 (29) | |
| Unknown | 32 (6) | 10 (9) | 15 (6) | 25 (7) | 7 (4) | |
| Grade (n = 289) | 0.19 | |||||
| 1 | 71 (24) | 19 (31) | 36 (26) | 55 (27) | 16 (18) | |
| 2 | 147 (51) | 29 (47) | 66 (47) | 95 (47) | 52 (60) | |
| 3 | 54 (19) | 10 (16) | 29 (21) | 39 (19) | 15 (17) | |
| Unknown | 17 (6) | 4 (6) | 9 (6) | 13 (6) | 4 (5) | |
| p53 IHC (n = 289) | >0.99 | |||||
| Positive | 72 (25) | 19 (31) | 31 (22) | 50 (25) | 22 (25) | |
| Negative | 196 (68) | 41 (66) | 95 (68) | 136 (67) | 60 (69) | |
| Unknown | 21 (7) | 2 (3) | 14 (10) | 16 (8) | 5 (6) |
aT/T + T/G genotypes versus G/G genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.